This is a working overview of glucagon receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-02-04. Anything still debated is marked as such rather than presented as settled.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Not a small molecule |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist activity |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also in aqueous buffers |
| Storage | −20 °C or below | Protect from light and moisture |
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
冻干粉通常在低温环境下保存，复溶之后需要按指定条件在较短时间内使用。反复冻融和剧烈振荡可能促进聚集，低吸附容器则能减少多肽在管壁上的损失。批号、日期与处理条件的完整记录，是后续复核与问题追溯的基础。
供应环节涉及来源核实与文件审核两类工作。分析证书、批次记录以及第三方检测报告构成常见的可追溯材料。来源不清的样品很难确认身份与纯度，因此核实步骤在实际操作中具有明确意义。缺少方法细节的报告通常无法复核。
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
== Medically significant species == Mortality (often determined by measured toxicity on mice) is a commonly used indicator of the danger of any given venomous snake, but important too are efficiency of venom delivery, venom yield, and behavior upon encountering humans. Given these additional, practical concerns, many snake experts have cited the black mamba and the coastal taipan as the world's most dangerous snakes – even though their venoms, drop for drop, are not the most lethal. Both species are elapids, and in several aspects of morphology, ecology and behavior, the coastal taipan is strongly convergent with the black mamba.
The word parlamento—of the same origin as Parliament in English—is used as a common name for all legislative assemblies, and hence parlamentario for the member of any of them, which can usually refer to members of:
A study in Europe suggested the gene marker is only relevant for East Asians. This has clinical relevance as it is agreed upon that prior to starting a medication such as allopurinol in a patient of Chinese descent, HLA-B*58:01 testing should be considered. Based on the Asian findings, similar studies in Europe showed 61% of allopurinol-induced SJS/TEN patients carried the HLA-B58 (phenotype frequency of the B*5801 allele in Europeans is typically 3%). One study concluded: "Even when HLA-B alleles behave as strong risk factors, as for allopurinol, they are neither sufficient nor necessary to explain the disease." Other HLA associations with the development of SJS, SJS/TEN, or TEN and the intake of specific drugs as determined in certain populations are given in HLA associations with SCARs.
==== Huo and Wang ==== In 1989–1993, Huo and Wang (中国社会科学院考古研究所, Zhongguo shehui kexueyuan kaogu yanjiusuo) tested the following caves: 224, 76, 4, 8, 34, 68, 77, 98, 104, 114, 117, 118, 119, 125, 129, 135, 162, 171, 180, 189, 196, 198, 206, 212, 219, 227, 27, 39, 48, 60, 69, 84, 91, 92, 99, 123, 139, 161, 165, 178, 207. They proposed a chronology which has some significant differences with the chronology previously proposed by Su Bai. Japanese teams of Nagoya University (日本名古屋大学) tested in 1995, 1997, 1998 and 2011 the following caves: 8, 171, 224, 13, 67, 76, 77, 92, 205. Many of the results remain inconclusive, sometimes even contradictory, and the historical period in question is rather too short in relation to the uncertainty margin of Carbon 14 datation, to provide a meaningful segmentation of the caves. Most narrow Carbon dates given for the Kizil Caves refer to a 68% probability level (1σ), which implies a significant level of uncertainty, and when dates are adjusted to the 95% probability level (2σ) as standard archaeological practice requires, then the timespan between the earliest and lowest dates becomes so large (about 200 to 300 years), as to make individual comparisons between the caves meaningless. Most researchers now use an approach combining artistic and architectural analysis together with carbon-dating, as a way to approach a reliable nomenclature, as proposed by Marylin Martin Rhie from 2001.
Sources: en.wikipedia.org
AS9100 Revision C (2009), Quality Management System – Requirements for Aviation, Space and Defense Organizations The update of AS9100 from revision B to C is largely to address the following question: "Our supplier is repeatedly late on delivery and failing to meet our requirements, how is it possible that they still have their AS9100 certificate?" That is, the AS9100C changes are driven by repeated delivery of non-conforming product and repeated late delivery by organizations that held AS9100A/B certifications. Those organizations had documented controls that conformed to the standard, however, there were insufficient processes in place to assure effectiveness of those controls. The response in this AS9100 revision is to elevate the requirements for Risk Management and to make Risk Management an integrated theme throughout the standard. A major challenge to AS9100B-compliant organizations was the new AS9100 auditing standards defined in AS9101 Revision D, which eliminates the clause-based compliance checklist and requires organizations to provide evidence of effectiveness of their systems and processes. Summary of changes between AS9100B and AS9100C:
An NTP binding site is a type of binding site found in nucleoside monophosphate (NMP) kinases, N can be adenosine or guanosine. A P-loop is one of the structural motifs common for nucleoside triphosphate (NTP) binding sites, it interacts with the bound nucleotide's phosphoryl groups. For the binding site to be able to bind a nucleotide, the nucleotide must be complex bound to Mg2+ or Mn2+. Nucleotide binding will cause conformational changes in the protein because the P-loop will bend. NTP binding sites play a role in poliovirus RNA replication. On the poliovirus RNA-dependent polymerase, also known as 3Dpol, there are two binding sites. Both binding sites contain lysine residues; however, only the lysine at position 61 is essential for RNA sequence elongation as part of the replication process. Additionally, a method known as computational alanine mutagenesis, has been used to find the key portions within the amino acid sequences that majorly characterize a particular NTP binding site; these regions within the sequence are conserved.
Nobelium is a synthetic chemical element; it has symbol No and atomic number 102. It is named after Alfred Nobel, the inventor of dynamite and benefactor of science. A radioactive metal, it is the tenth transuranium element, the second transfermium, and is the fourteenth member of the actinide series. Like all elements with atomic number over 100, nobelium can only be produced in particle accelerators by bombarding lighter elements with charged particles. A total of twelve nobelium isotopes are known to exist; the most stable is 259No with a half-life of 58 minutes, but the shorter-lived 255No (half-life 3.1 minutes) is most commonly used in chemistry because it can be produced on a larger scale. Chemistry experiments have confirmed that nobelium behaves as a heavier homolog to ytterbium in the periodic table. The chemical properties of nobelium are not completely known: they are mostly only known in aqueous solution. Before nobelium's discovery, it was predicted that it would show a stable +2 oxidation state as well as the +3 state characteristic of the other actinides; these predictions were later confirmed, as the +2 state is much more stable than the +3 state in aqueous solution and it is difficult to keep nobelium in the +3 state. In the 1950s and 1960s, many claims of the discovery of nobelium were made from laboratories in Sweden, the Soviet Union, and the United States. Although the Swedish scientists soon retracted their claims, the priority of the discovery and therefore the naming of the element was disputed between Soviet and American scientists.
11 December – Researchers demonstrate the use of biological-electronic hybrid Organoid Intelligence, 'Brainoware' (see 1 March), for speech recognition. 12 December – Asteroid 319 Leona occults the bright star Betelgeuse for about 12 seconds as viewed on a narrow path from China to Mexico. 13 December Scientists report that the contents of the sample-return mission of the OSIRIS-REx mission to asteroid Bennu revealed organic molecules as well as unknown materials which require more study to have a better idea of their composition and makeup. The smallest known brown dwarf, weighing just three to four times the mass of Jupiter, is discovered in star cluster IC 348 by astronomers using the James Webb Space Telescope.
=== Synthesis === One method for preparing β-phenethylamine, set forth in J. C. Robinson and H. R. Snyder's Organic Syntheses (published 1955), involves the reduction of benzyl cyanide with hydrogen in liquid ammonia, in the presence of a Raney-Nickel catalyst, at a temperature of 130 °C and a pressure of 13.8 MPa. Alternative syntheses are outlined in the footnotes to this preparation. A much more convenient method for the synthesis of β-phenethylamine is the reduction of ω-nitrostyrene by lithium aluminium hydride in ether, whose successful execution was first reported by R. F. Nystrom and W. G. Brown in 1948. Phenethylamine can also be produced via the cathodic reduction of benzyl cyanide in a divided cell.
Sources: en.wikipedia.org
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.
Earlier incretin therapies engage one or two receptors. Retatrutide adds glucagon receptor activity, which may raise energy expenditure. Whether this produces larger clinical benefits is still being tested.
It has completed phase 2 trials and moved into later-stage evaluation. No regulator has granted approval. Access outside research settings is not authorized.
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.